Company intelligence / Profile preview

Elixir Medical

Milpitas, California, United Stateselixirmedical.com ↗

Ownership: Private
Development stage: Commercial

Overview

Elixir Medical’s DynamX bioadaptor implant has demonstrated significant reductions (>80%) in adverse events compared to best-in-class drug-eluting stents across two randomized controlled trials, with consistent results across geographies and complex patient populations. The LithiX Hertz Contact IVL system recently received CE Mark approval for treating calcified coronary lesions.

Therapeutic areas: Cardiovascular
Modalities: DeviceDrug-device combination (for drug-eluting stents)Mechanical intravascular lithotripsy system
Industry: Implantable Medical Devices

Drug pipeline

2 assets

DynamX Coronary Bioadaptor System

Commercial

Indications: Coronary artery disease

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Elixir Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elixir Medical.

Explore the full profile